Trial Profile
A phase I, dose escalation and pharmacokinetics study of temperature sensitive liposome encapsulated doxorubicin (ThermoDox) and hyperthermia in patients with local-regionally recurrent breast cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
- 04 Sep 2014 Results published in the Media Release.
- 09 Sep 2013 Results have been presented at the 2013 San Antonio Breast Cancer Conference according to a Celsion Corporation media release.